Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling
Langerhans cell histiocytosis (LCH) is a rare disease that has a variable clinical presentation and unpredictable behavior. Until recently, therapeutic options were limited. Insights into the role of mitogen-activated protein kinase (MAPK) signaling have allowed the increased use of targeted treatme...
Zapisane w:
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2021-11-01
|
| Seria: | Biomedicines |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/2227-9059/9/12/1759 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|